BioSpace News Archive

Natera, Inc., a global leader in cell-free DNA testing, announced that members of its management team will present at the following investor conferences: The Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11 at 4:55 p.m. ET in New York, NY The Baird 2023 Global Healthcare Conference on Tuesday, Sept.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) announced that the Company’s Special Meeting of Stockholders (the “Special Meeting”) held on August 31, 2023 at 9:00 a.m.

Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the Saskatchewan Drug Plan Formulary for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.

ANGUS Chemical Company announced the completion of its corporate rebrand and corporate name change to Advancion Corporation, effective September 1, 2023.

For decades, many scientists have described the blood-brain barrier—a tight network of cells that separates the brain from the blood—as a nearly impenetrable border wall. But Andrew C. Yang, PhD, who is joining Gladstone Institutes as an assistant investigator, thinks there’s more to it than that.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study.

Cytokinetics, Incorporated announced that on August 31, 2023 it granted stock options to purchase an aggregate of 77,800 shares of common stock to 4 new employees, whose employment commenced in August 2023, as a material inducement to their employment.

Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 58,850 restricted stock units to six newly-hired employees.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 3,250 restricted stock units of Atara’s common stock to one newly hired employee.